Summary
Identification of an amiodarone metabolite in the plasma of patients receiving a single dose of the drμg was carried out by mass-spectrometry following extraction and HPLC separation.
The kinetics of the plasma concentrations of unchanged compound and its identified metabolite (N-monodesthyl-amiodarone) were studied in six patients after a single adiministration of amiodarone by oral or intravenous routes, using a sensitive and specific high-performance liquid chromatographic method. The observed plasma clearance rate for the drμg varied from 0.2 to 0.5 l.h−1.kg−1 of body weight; and the elimination half-life of the unchanged compound was found to be approximately 21 hours. Oral bioavailability, as determined in one patient, was about 60%.
The proportion of the metabolite found in the plasma following a single oral administration was significantly higher than that observed after infusion. The ratio of areas under the curves for metabolite-to-unchanged compound was 0.55 and 0.13 for oral and intravenous doses respectively. During a circumscribed study carried out in five patients receiving oral doses of the drμg (daily dose varied from 2.6 to 9.3 mg/kg) accumulation of the metabolite was observed. The mean of the plasma level ratios (metabolite to-unaltered drμg) obtained in five patiens was approximately 0.97.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Vastesaeger M., Gillot P. and Rasson G. (1967): Etude clinique d’une nouvelle médication antiangoreuse., Acta Cardiol.,22, 483–500.
Daubert J.C. and Gouffault J. (1977): Etude clinique de l’Amiodarone injectable, Coeur Med. Interne,16, 415–421.
Van Schepdael J. and Solvay H. (1970): Etude clinique de l’Amiodarone dans les troubles du rythme cardiaque, Presse Med.,78, 1849–1850.
Broekhuysen J., Laruel R. and Sion R. (1969): Recherche dans la série des benzofuranes XXXVII: Etude comparée du transit et du métabolisme de l’amiodarone chez diverses espèces animales et chez l’homme, Arch. Int. Pharmacodyn. Ther.,177, 340–359.
Andreasen F., Agerbaek H., Bjerregaard P., Gotzsche H. and Jensen L.D. (1981): Pharmacokinetic of amiodarone after intravenous and oral administration, Eur. J. Clin. Pharmacol.,19, 293–299.
Flanagan R.J., Storey G. C-A. and Holt D.N. (1980): Rapid high-performance liquid chromatographic method for the measurement of amiodarone in blood plasma or serum at the concentrations attained during therapy, J. Chromatogr.,187, 391–398.
Canada A.T., Lesko L.J. and Haffajee C.I. (1980): Pharmacokinetics of amiodarone in patients with life threatening tacchyarrhythmias, conference abstracts No 319, World Conference on Clinical Pharmacology and Therapeutics, London, England.
Cano J.P., Gazerian J., Sommadossi J.P., Iliadis A., Fornaris M., Serradimigni A., Egré A., and Djiane P. (1980): Pharmacocinétique de l’Amiodarone après administration par perfusion, résultats préliminaires. Antiarrhythmic and antianginal drμgs with cumulative effects, Proceeding of the VIIIth European Congress of Cardiology, Paris, France.
Pacco P., Sion R., Matteazzi J.R., and Nokin P. (1983): Pharmacokinetic properties of amiodarone in the dog. (In preparation).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marchiset, D., Aubert, C., Sumirtapura, Y.C. et al. Mass spectrometric identification of amiodarone N-monodesethyl metabolite and application of an HPLC method to a pharmacokinetic study. European Journal of Drug Metabolism and Pharmacokinetics 9, 123–128 (1984). https://doi.org/10.1007/BF03189615
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03189615